Lustgarten Foundation K-ras Targeted Drug Discovery

2010 Request For Applications: K-ras Targeted Drug Discovery
Release Date: May 14, 2010

Concept Proposal Due Date: June 14, 2010
Full Proposal Requests within 4-6 weeks


The Lustgarten Foundation invites collaborative or individual applications proposing innovative approaches to target K-ras. Pancreatic cancers are one of the most lethal of all cancers and studies have found that up to 95% contain K-ras mutations. Therefore, the Foundation is prepared to allocate a significant portion of its multi-million dollar budget to this K-ras program.

Interested applicants should submit a Concept Proposal by June 14, 2010. The Foundation will contact the Principal Investigators of selected concepts to request detailed proposals.



Eligibility Requirements

Applications may be submitted by domestic or foreign, non-profit or for-profit organizations, public or private, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.

Mechanism of Support

Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. Given the urgent need for therapies, we encourage projects that can make the largest impact in the shortest time. The total project period for an application submitted in response to this RFA may not exceed three years and will be subject to yearly review by The Lustgarten Foundation and its review board.

Concept Proposal

Prospective applicants are asked to submit a Concept Proposal that addresses specific questions as outlined in the Guidelines. The deliverables of the proposed research should be compound(s) that inhibits K-ras function in cells in vitro and in vivo. The proposal should therefore focus on drug discovery rather than on the discovery of potential drug targets. All sorts of therapeutic agents will be considered, though approaches that employ macromolecules (antibodies, genes, siRNA, etc.) must include documentation that the agent can be delivered to the vast majority of tumor cells in an animal model.

Concept Proposals should be sent to Mila McCurrach at mmccurra@cablevision.com no later than 5pm EST on June 14, 2010.

https://www.lustgarten.org/Page.aspx?pid=666&srctid=1&erid=1306398